A Tragic Reminder: How an Unchecked Gene‑Editing Experiment Cost a Young Girl Her Life

When the parents of a six‑year‑old girl in Shanghai learned that a local research team claimed to have a "world‑first" brain‑targeted gene‑editing treatment, hope surged. Their child, diagnosed with Snijders Blok‑Campeau syndrome – a rare condition caused by a single mutation in the CHD3 gene – faced learning difficulties, speech delays and occasional seizures. Most people with the syndrome, however, manage to lead relatively normal lives.

Desperate for any chance to improve their daughter’s future, the family travelled to Shanghai Jiao Tong University, where neuroscientist Zilong Qiu and his team were running a personalized, experimental trial. The approach was not the older CRISPR‑Cas9 system that slices DNA in both strands. It was a newer technique called base‑editing, invented by American biochemist David Liu at the Broad Institute in 2016. In theory, base‑editing swaps one DNA letter for another – for example, turning a "C" into a "T" – without the double‑helix breakage that often creates unwanted mutations.

On paper, the method sounded gentler, more precise, and therefore a logical next step for treating single‑gene disorders. The researchers announced they were delivering the edit directly into the brain, a bold claim that would make the case the first ever "first‑in‑human" base‑editing therapy aimed at neural tissue.

Tragically, the girl died in March 2025, just weeks after the infusion. An investigation by Science and the watchdog group Retraction Watch pieced together a disturbing picture: the trial had proceeded with scant external oversight, limited public disclosure, and an apparent mismatch between the experimental risk and the disease’s natural course.

Snijders Blok‑Campeau syndrome is undeniably serious, yet its spectrum ranges from mild learning challenges to more pronounced cognitive impairment. Most patients, even those on the severe end, survive into adulthood. Critics argue that the gamble – a high‑risk brain intervention – was disproportionate to the potential benefit, especially when less invasive therapies (speech therapy, educational support, and off‑label medication) could have been pursued.

The case also resurrects memories of He Jiankui, the Chinese researcher who, in 2018, announced the birth of the world’s first CRISPR‑edited babies. That scandal prompted China to tighten regulations, establishing stricter ethics committees and a national oversight framework. Yet the recent tragedy suggests that loopholes remain, particularly for novel tools like base‑editing that sit in a regulatory grey zone.

Several unanswered questions linger. Who granted the experimental protocol its green light? Were the parents fully briefed on the uncertain risk profile, or were they presented with an overly optimistic narrative? And why did the institution allow a single‑patient, "personalized" trial to bypass the more rigorous Phase‑1 safety studies usually required for first‑in‑human work?

Scientists worldwide are now grappling with the broader implications. The allure of correcting a single genetic mistake is powerful, but without transparent, independent review, the line between visionary medicine and reckless experimentation can blur. Many ethicists warn that societies, especially those eager to showcase scientific prowess, risk treating disability as a problem to be erased rather than a difference to be respected.

As the Chinese authorities launch a formal probe, families of other rare‑disease patients watch closely. Their hope is that stricter safeguards will emerge – not to stifle innovation, but to ensure that the next breakthrough does not come at the cost of a child’s life.

Until then, the girl's story stands as a sobering reminder: cutting‑edge science, however promising, must be anchored in robust oversight, clear communication, and an unwavering respect for human life.